Capula Management’s Twist Bioscience TWST Stock Holding History

Capula Management’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-43,520	Closed	-$882K	–	575
2023 Q3	$882K	Buy	+43,520	New	+$956K	0.02%	249
2023 Q2	–	Sell	-20,920	Closed	-$315K	–	788
2023 Q1	$315K	Sell	20,920 -16,360	-44%	-$361K	﹤0.01%	519
2022 Q4	$888K	Buy	+37,280	New	+$1.08M	0.01%	477

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capula Management's TWST Position: Q4 2023 in Review

Capula Management sold out of Twist Bioscience (TWST) in Q4 2023, closing a stake of 43,520 shares — an estimated $882K sold.

Capula Management first reported a position in TWST in Q4 2022 and held it in 3 quarters. The position peaked at $888K in Q4 2022. 218 funds tracked by Wall St. Rank hold TWST as of Q4 2023.

Capula Management reported no remaining Twist Bioscience position as of Q4 2023 after selling out during the quarter.
Capula Management sold 43,520 Twist Bioscience shares in Q4 2023, an estimated $882K.
Capula Management first reported a position in Twist Bioscience in Q4 2022 and held it in 3 quarters.
Capula Management's Twist Bioscience position peaked at $888K in Q4 2022.
218 funds tracked by Wall St. Rank held Twist Bioscience as of Q4 2023.

Based on Capula Management's 13F filing for Q4 2023, filed 12 Feb 2024.